Data / Drug companies / Peroxisome Proliferator Receptor alpha Agonist

Peroxisome Proliferator Receptor alpha Agonist drugs: 12 drugs from 77 companies in the FDA NDC directory

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Peroxisome Proliferator Receptor alpha Agonist is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 359 products in this class from 77 companies, covering 12 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on September 24, 2026.

The request: Get every company that lists a Peroxisome Proliferator Receptor alpha Agonist drug in the FDA NDC directory, with headquarters, website and size. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

• 77Companies
• 359Products
• 12Drugs by generic name

Drugs in the Peroxisome Proliferator Receptor alpha Agonist class

Ranked by number of companies that list the drug.

Companies with the most products in this class

Dosage forms

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.